menu
    • menu
    [{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Not Applicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Dociparstat sodium","moa":"HMGB1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/ Not Applicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Chimerix","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Chimerix","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.37,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.37,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dordaviprone","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Not Applicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dordaviprone","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Not Applicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Oncoceutics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chimerix \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Chimerix \/ Chimerix"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"ClpP\/D2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Chimerix

    Menu

    Chimerix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chimerix Announces FDA Acceptance and Priority Review of NDA for Dordaviprone

                            Details : ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.

                            Product Name : ONC201

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chimerix Submits Dordaviprone NDA for Accelerated Approval Of Recurrent Diffuse Glioma

                            Details : ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 30, 2024

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chimerix to Submit Dordaviprone for Accelerated Approval in for H3 K27M-Mutant Glioma

                            Details : ONC201 (dordaviprone) targets the targets the mitochondrial protease ClpP and dopamine receptor D2. It is being evaluated for the treatment of recurrent H3 K27M-mutant diffuse glioma.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2024

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference a...

                            Details : ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.

                            Product Name : ONC201

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Biomedical Advanced Research and Development Authority

                            Deal Size : $374.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

                            Details : Collaboration with BARDA for the development of TEMBEXA (brincidofovir) has provided the United States government with a second therapeutic option to ensure the federal government’s readiness for a potential smallpox emergency.

                            Product Name : Tembexa

                            Product Type : Small molecule

                            Upfront Cash : $238.0 million

                            August 29, 2022

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Biomedical Advanced Research and Development Authority

                            Deal Size : $374.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Public Health Agency of Canada

                            Deal Size : $25.3 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of ...

                            Details : Chimerix signed a contract agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolution...

                            Product Name : Tembexa

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 24, 2022

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Public Health Agency of Canada

                            Deal Size : $25.3 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Emergent BioSolutions

                            Deal Size : $9.3 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

                            Details : Chimerix expects to promptly provide treatment courses of TEMBEXA (brincidofovir) equivalent to the total value of the procurement contract. Execution of this contract will be the responsibility of Chimerix.

                            Product Name : Tembexa

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 23, 2022

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Emergent BioSolutions

                            Deal Size : $9.3 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Emergent BioSolutions

                            Deal Size : $325.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), th...

                            Details : TEMBEXA (brincidofovir), is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.

                            Product Name : Tembexa

                            Product Type : Small molecule

                            Upfront Cash : $225.0 million

                            May 16, 2022

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Emergent BioSolutions

                            Deal Size : $325.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dociparstat sodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT

                            Details : The primary endpoint of the study is survival without the need for mechanical ventilation through day 28. The first cohort enrolled 12 patients randomized 1:1. One patient on DSTAT was ventilated and recovered.

                            Product Name : DSTAT

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 25, 2021

                            Lead Product(s) : Dociparstat sodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Chimerix

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Oncoceutics Inc

                            Deal Size : $78.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

                            Details : ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation.

                            Product Name : ONC201

                            Product Type : Cytotoxic Drug

                            Upfront Cash : $39.0 million

                            January 08, 2021

                            Lead Product(s) : Dordaviprone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Oncoceutics Inc

                            Deal Size : $78.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth